R.A. Mashelkar: the engineer behind India's affordable drug revolution

Raghunath Anant Mashelkar is one of those rare Indian scientists whose influence stretches far beyond the laboratory. Across four decades he has shaped how a billion-strong nation thinks about medicine, intellectual property, and the moral duty of science to serve the poor. His name has become shorthand for innovation that is sophisticated, socially conscious, and committed to the principle that lifesaving drugs should not be luxuries.

Trained as a chemical engineer, Mashelkar rose to lead the Council of Scientific and Industrial Research, India's largest network of public laboratories. From that vantage point he pushed CSIR into unfamiliar territory: the politics of pharmaceutical pricing, the ethics of patent law, and the architecture of international research collaborations. Scientific temper, he insisted, demanded action as well as curiosity.

His most enduring legacy is the campaign to dismantle monopolies on essential medicines. Whether negotiating in Geneva or rallying Indian generic manufacturers, Mashelkar has argued that innovation and affordability are partners in a single project of human development.

This is the story of how a boy from a small town in Maharashtra helped rewrite the rules of pharmaceutical access, and what that story still has to teach a world where medicine costs continue to climb.

From humble Maharashtra to the frontiers of chemical engineering

Mashelkar was born in 1943 in Mashel, a village in coastal Maharashtra. His schooling was in Marathi-medium institutions, and he has often said that access to a good library, rather than wealth, shaped his trajectory. He earned a chemical engineering degree from the University of Bombay and a PhD from the University of London, where his work on non-Newtonian fluids earned international recognition.

Returning to India in 1976, he joined the National Chemical Laboratory in Pune, a long-standing capital of Indian science. There he built a research group producing more than 250 papers and trained a generation of scientists who went on to senior positions in academia and industry.

Building CSIR into a global research powerhouse

In 1995, Mashelkar was appointed Director General of CSIR, an umbrella organisation coordinating thirty-eight laboratories across India. He refocused the network around scientific excellence and societal relevance, encouraging laboratory directors to spend time in villages and observe how research could address real problems.

He positioned CSIR as a bridge between India's emerging pharmaceutical industry and its public health priorities, particularly through partnerships with manufacturers in Hyderabad and Ahmedabad. The shift drew critics, but it gave CSIR a renewed sense of public legitimacy.

The battle for affordable AIDS drugs

The most dramatic episode in Mashelkar's public life came in the early 2000s, when Indian generics came under pressure from multinationals seeking stronger patent protection. Mashelkar emerged as one of the most articulate scientific voices arguing that India's 1970 Patent Act had been instrumental in building a generic industry that supplied affordable medicines to the developing world.

When India moved toward a TRIPS-compliant regime in 2005, he argued for a "second-generation" patent system that protected genuine innovation while preserving space for compulsory licensing and public health safeguards. The policy he defended has kept first-line antiretrovirals within reach of millions across Africa, Asia and Latin America.

Open source drug discovery: a new model

In 2008, Mashelkar launched the Open Source Drug Discovery initiative, applying the logic of open-source software to the search for new treatments for neglected tropical diseases. The premise was simple: if researchers worldwide contributed their work freely, the cost of drug discovery could fall dramatically.

OSDD attracted researchers from dozens of countries and influenced how global funders think about collaborative science. For observers in Australia, where the Therapeutic Goods Administration oversees one of the world's most rigorous regulatory regimes, OSDD offers a contrasting model of openness worth debating.

Patents, policy and the generic medicine movement

Mashelkar chaired several influential committees on Indian intellectual property law, including the technical group that examined amendments to patent legislation in the mid-2000s. He consistently argued that intellectual property regimes must be measured by how they shape innovation incentives and how they affect access to essential goods.

Indian generic manufacturers have built a global reputation for producing high-quality medicines at a fraction of branded prices, supplying both the Pharmaceutical Benefits Scheme in Australia and national drug programmes across Africa. The science-policy framework Mashelkar helped articulate is one reason those supply chains remain robust.

Recognition, influence and a global profile

Mashelkar has received three of India's highest civilian honours, including the Padma Vibhushan, and has been elected to the Royal Society and the US National Academy of Sciences. He has advised governments from Tokyo to Washington, yet remains closely associated with Pune. For a generation of Indian scientists, he is proof that public science can be globally competitive without losing its social roots.

For young researchers in cities like Melbourne, where the biomedical sector has grown around the Parkville precinct, his career offers an instructive counterpoint. The parallel with CSIRO, which has long wrestled with the same balance, is hard to miss.

Where to start if this story has caught your attention

For readers who want to dig deeper, the following threads are worth following. Mashelkar's career intersects with several ongoing debates, and each offers its own entry point into a larger story.

The suggestions below cover primary sources, regulatory contexts, and current policy debates. None of them requires more than an afternoon, and together they should give a balanced sense of where the field stands today.

For all the global attention his work has attracted, the practical lesson is remarkably local. Affordable medicine depends on the unglamorous plumbing of policy: a national laboratory network, a credible regulator, a public procurement system, and a legal framework that lets competitors enter the market. Australia's PBS and India's generic industry are, in different ways, products of that plumbing, and each has lessons for the other.